Study of additional treatment after surgery in endometrial cancer
- Conditions
- Health Condition 1: C541- Malignant neoplasm of endometrium
- Registration Number
- CTRI/2024/08/072343
- Lead Sponsor
- eiden University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Histologically confirmed diagnosis of EC of the following histologic subtypes: endometrioid
endometrial carcinoma, serous endometrial carcinoma, uterine clear cell carcinoma,
dedifferentiated and undifferentiated endometrial carcinoma, uterine carcinosarcoma, and
mixed endometrial carcinomas of the aforementioned histotypes.
Full molecular classification performed following the diagnostic algorithm described in WHO
2020 (5th Edition, IARC, Lyon, 2020, adapted from Vermij et al. 2020)
TLH-BSO or TAH-BSO with or without lymphadenectomy or sentinel node biopsy, without
macroscopic residual disease after surgery
No distant metastases as determined by pre-surgical or post-surgical imaging (CT/MRI scan
of chest, abdomen and pelvis or PET-CT scan)
History of another primary malignancy, except for non-melanoma skin cancer, in the past 5
years
Prior pelvic irradiation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method